Table 1 Lung cancer patients - samples characteristics.

From: Blood Serum Calorimetry Indicates the Chemotherapeutic Efficacy in Lung Cancer Treatment

Sample (response to chemotherapy)

Total Proteins [mg·mL−1]

Albumin[%]

Sex

Smoking

Lung Cancer Type

LC-a1 (smLC)

75.0

58.7

M

Yes

Adenocarcinoma

LC-a2 (smLC)

75.0

58.5

F

No

Adenocarcinoma

LC-a3* (pLC)

67.0

57.2

F

No

Adenocarcinoma

LC-s4 (smLC)

68.0

58.5

F

No

Squamous cell carcinoma

LC-s5 (smLC)

65.0

62.5

M

Yes

Squamous cell carcinoma

LC-a6 (smLC)

78.0

55.6

F

No

Adenocarcinoma

LC-a7* (pLC)

65.0

60.1

F

No

Adenocarcinoma

LC-a8* (pLC)

76.0

56.6

F

No

Adenocarcinoma

LC-a9 (smLC)

66.0

64.5

F

Yes

Adenocarcinoma

LC-a10 (smLC)

64.0

62.5

M

Yes

Adenocarcinoma

LC-a11 (smLC)

62.0

62.3

M

Yes

Adenocarcinoma

  1. A patient who responds to chemotherapy treatment is referred as smLC (stable metastatic lung cancer), whereas patient non-responding to the chemotherapy is referred as pLC* (progressive lung cancer).